It is understandable to worry about regaining weight when treatment ends. Studies show that regain is common, but they cannot predict your individual course. Planning follow-up and discussing changes early is more useful than treating the end of a prescription as the end of care.
What the STEP-1 extension examined
In a follow-up of 327 participants, both the studied semaglutide treatment and structured lifestyle support ended after 68 weeks. During the following year, the previously semaglutide-treated group regained, on average, about two-thirds of the weight they had previously lost.
This describes a group, not an inevitable outcome for each person. Because support also ended, the study does not isolate medication withdrawal while the same support continues. Novo Nordisk funded the research, and selection of the follow-up subgroup further limits how broadly it can be applied.
What SURMOUNT-4 adds
Following an initial period when everyone received tirzepatide, SURMOUNT-4 compared continuing treatment with switching to placebo. Adults without diabetes continued receiving support. Over the subsequent 52 weeks, mean weight in the placebo group increased by 14.0% relative to the switch point, while it fell further with continued treatment.
That 14% is not the proportion of previously lost kilograms regained. The reference is body weight at randomisation. Eli Lilly funded the study. Its findings concern the selected population and tested approach, rather than every possible treatment situation.
Read the numbers carefully
Always ask: a percentage of what, over which period and in which people? A proportion of previous weight loss and a percentage change in body weight are different calculations. They should not be presented alongside each other as if they were interchangeable.
An average also provides no personal threshold for declaring treatment a failure. Some individuals change more, others less. If a chart is unclear, consult the study or the percentage explainer before turning a headline into a treatment decision.
Agree follow-up before stopping
Discuss why a change is being considered: tolerability, cost, life circumstances or a different medical goal. Clarify who will provide care afterwards, which health measures matter and when your next appointment will take place. An ending prescription should not automatically mean support ends too.
Follow-up can include practical food routines, activity within your abilities and discussion of returning hunger or distress around eating. WHO describes obesity as a chronic condition requiring long-term care. That does not mean every person must take every medicine for life.
Respond to regain without blame
If you are already regaining, arrange a review and bring a timeline. Describe changes in appetite, sleep, symptoms and access to care. One measurement tells less than an understandable pattern together with how you are feeling.
Avoid punishing yourself with severe restriction or independently restarting leftover medicine. A previous dose is not automatically appropriate after an interruption. Your care team needs to discuss with you which next steps fit the present situation.
Common questions
Do these studies prove that stopping is always wrong?
No. They identify a meaningful risk of regain under the conditions studied. Personal reasons for change and planned follow-up remain important.
Does slowly tapering guarantee prevention of regain?
No such guarantee follows from these studies. They are not a universal tapering guide. Discuss changes professionally rather than adopting a schedule from social media.
Sources & further reading
- Wilding et al. 2022: STEP-1-Verlängerung nach Semaglutid
- Aronne et al. 2024: SURMOUNT-4
- WHO: GLP-1-Leitlinie zur langfristigen Adipositasversorgung
Sources checked:
Questions and experiences
Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.
Loading reader contributions…
Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact